Fung L

Language: English
References: 4
Page: s125-s125
PDF size: 103.25 Kb.

Text Extraction

Transfusion-Related Acute Lung Injury (TRALI) remains a leading cause of transfusion-associated mortality. TRALI is considered to follow a twoevent model: the first event is the patient’s illness, which leads to pulmonary endothelial activation and neutrophil sequestration; the second event is the subsequent transfusion, which contains an agent that precipitates lung injury.1 In the majority of laboratory-investigated TRALI cases, anti-HLA and anti-HNA antibodies have been implicated in immune-mediated TRALI, with antibodies to HLA class II and HNA-3a being associated with clinically severe and some fatal cases.

REFERENCES

1. Tung JP, Chiaretti S, Dean MM, Sultana AJ, Reade MC, Fung YL.Transfusion-related acute lung injury (TRALI): Potential pathwaysof development, strategies for prevention and treatment, andfuture research directions. Blood Rev. 2022; 100926.

2. Reil A, Keller-Stanislawski B, Gunay S, Bux J. Specificities ofleucocyte alloantibodies in transfusion-related acute lung injuryand results of leucocyte antibody screening of blood donors. VoxSang. 2008; 95 (4): 313-317.

3. Fung YL, Tung JP. Non-antibody mediated transfusion-relatedacute lung injury an enigma. Ann Blood. 2019; 4: 7.

4. Fung YL, Tung JP. How different animal models help usunderstand TRALI. ISBT Sci Series. 2018; 13 (3): 197-205.